EE9800151A - 3-spiroindolin-2-ooni derivaadid kui vasopressiini- ja/või oksütotsiiniretseptorite ligandid - Google Patents

3-spiroindolin-2-ooni derivaadid kui vasopressiini- ja/või oksütotsiiniretseptorite ligandid

Info

Publication number
EE9800151A
EE9800151A EE9800151A EE9800151A EE9800151A EE 9800151 A EE9800151 A EE 9800151A EE 9800151 A EE9800151 A EE 9800151A EE 9800151 A EE9800151 A EE 9800151A EE 9800151 A EE9800151 A EE 9800151A
Authority
EE
Estonia
Prior art keywords
spiroindolin
vasopressin
ligands
derivatives
oxytocin receptors
Prior art date
Application number
EE9800151A
Other languages
English (en)
Other versions
EE04433B1 (et
Inventor
Foulon Lo�c
Garcia Georges
Serradeil-Le Gal Claudine
Valette Grard
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of EE9800151A publication Critical patent/EE9800151A/et
Publication of EE04433B1 publication Critical patent/EE04433B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9800151A 1995-10-24 1996-10-24 3-spiroindolin-2-ooni derivaadid kui vasopressiini- ja/või oksütotsiiniretseptorite ligandid, nendevalmistamismeetod, neid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine ravimite valmistamiseks EE04433B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512533A FR2740136B1 (fr) 1995-10-24 1995-10-24 Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
PCT/FR1996/001666 WO1997015556A1 (fr) 1995-10-24 1996-10-24 Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine

Publications (2)

Publication Number Publication Date
EE9800151A true EE9800151A (et) 1998-12-15
EE04433B1 EE04433B1 (et) 2005-02-15

Family

ID=9483867

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800151A EE04433B1 (et) 1995-10-24 1996-10-24 3-spiroindolin-2-ooni derivaadid kui vasopressiini- ja/või oksütotsiiniretseptorite ligandid, nendevalmistamismeetod, neid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine ravimite valmistamiseks

Country Status (31)

Country Link
US (2) US5994350A (et)
EP (1) EP0873309B1 (et)
JP (2) JP3274471B2 (et)
KR (1) KR100298925B1 (et)
CN (1) CN1106384C (et)
AR (1) AR004225A1 (et)
AT (1) ATE229940T1 (et)
AU (1) AU715841B2 (et)
BR (1) BR9611198A (et)
CZ (1) CZ295585B6 (et)
DE (1) DE69625517T2 (et)
DK (1) DK0873309T3 (et)
EE (1) EE04433B1 (et)
ES (1) ES2191769T3 (et)
FR (1) FR2740136B1 (et)
HK (1) HK1016596A1 (et)
HU (1) HUP9900331A3 (et)
IL (1) IL124002A (et)
IN (1) IN185328B (et)
IS (1) IS1949B (et)
MY (1) MY115864A (et)
NO (1) NO310974B1 (et)
NZ (1) NZ320352A (et)
PL (1) PL187093B1 (et)
RU (1) RU2167864C2 (et)
SK (1) SK284546B6 (et)
TR (1) TR199800719T2 (et)
TW (1) TW474917B (et)
UA (1) UA59345C2 (et)
WO (1) WO1997015556A1 (et)
ZA (1) ZA968945B (et)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2775598A1 (fr) 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
HU225150B1 (en) * 1999-07-15 2006-07-28 Sanofi Aventis Novel process for producing 2-methoxy-4-(t-butylaminocarbonyl)-benzenesulfonyl chloride
HUP9902376A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing n-(1,1-dimethyl)-4-[[s'-ethoxi-4-cis-[2-(4-morpholino)-ethoxi]-2'-oxospiro[cyclohexane-1,3'-[3h]indole]-1'(2'h)yl]-sulfonyl]-3-methoxybenzamide and its salts
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US7056910B2 (en) * 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
CA2432825A1 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
AU2002247127A1 (en) 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
DK1421064T3 (da) * 2001-07-31 2005-08-29 Sanofi Aventis Fremgangsmåde til fremstilling af 3-spiro[cyclohexan-1,3'-[3H]indolin-2'-on] derivater
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
FR2874921B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one, leur preparation et leur application en therapeutique
FR2874920B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one comme ligand des recepteurs de la vasopressine
MX2007007103A (es) * 2004-12-13 2008-03-10 Lilly Co Eli Derivados espiro como inhibidores de lipoxigenasa.
JP2008526702A (ja) * 2004-12-31 2008-07-24 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
JP5570172B2 (ja) * 2008-10-08 2014-08-13 持田製薬株式会社 喫煙による循環機能不全の予防／改善または治療剤
NZ592275A (en) 2008-10-17 2013-04-26 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
MD4202C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbometoxi ai spiro[ciclopropan-oxindolilor]
MD4201C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbonitrilici ai spiro[ciclopropan-oxindolilor]
US9657021B2 (en) * 2013-03-08 2017-05-23 Wockhardt Limited Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]-octane
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
TR199800719T2 (xx) 1998-08-21
MY115864A (en) 2003-09-30
CN1202886A (zh) 1998-12-23
US5994350A (en) 1999-11-30
TW474917B (en) 2002-02-01
AU715841B2 (en) 2000-02-10
KR100298925B1 (ko) 2001-09-06
EP0873309A1 (fr) 1998-10-28
PL187093B1 (pl) 2004-05-31
NO981817L (no) 1998-04-23
PL326555A1 (en) 1998-09-28
ES2191769T3 (es) 2003-09-16
JPH11509232A (ja) 1999-08-17
AR004225A1 (es) 1998-11-04
JP3274471B2 (ja) 2002-04-15
AU7308096A (en) 1997-05-15
IS1949B (is) 2004-10-13
NO310974B1 (no) 2001-09-24
NO981817D0 (no) 1998-04-23
FR2740136B1 (fr) 1998-01-09
DK0873309T3 (da) 2003-03-17
IN185328B (et) 2000-12-30
CZ295585B6 (cs) 2005-08-17
NZ320352A (en) 2000-01-28
HUP9900331A3 (en) 1999-11-29
ATE229940T1 (de) 2003-01-15
ZA968945B (en) 1997-05-29
CZ126798A3 (cs) 1998-08-12
RU2167864C2 (ru) 2001-05-27
FR2740136A1 (fr) 1997-04-25
JP2001302631A (ja) 2001-10-31
BR9611198A (pt) 1999-04-06
KR19990067056A (ko) 1999-08-16
CN1106384C (zh) 2003-04-23
US6046341A (en) 2000-04-04
SK49098A3 (en) 1998-09-09
HUP9900331A2 (hu) 1999-05-28
IS4714A (is) 1998-04-14
EP0873309B1 (fr) 2002-12-18
DE69625517D1 (de) 2003-01-30
WO1997015556A1 (fr) 1997-05-01
DE69625517T2 (de) 2003-09-11
IL124002A (en) 2002-11-10
HK1016596A1 (en) 1999-11-05
UA59345C2 (uk) 2003-09-15
SK284546B6 (sk) 2005-06-02
EE04433B1 (et) 2005-02-15
MX9803269A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
EE9800151A (et) 3-spiroindolin-2-ooni derivaadid kui vasopressiini- ja/või oksütotsiiniretseptorite ligandid
PT805813E (pt) Antagonistas de vasopressina triciclicos
DE69605205D1 (de) Gefaltete filteranordnung
DE69617699D1 (de) Neuartige opioid-peptide
PT804438E (pt) Benzazepinas triciclicas antagonistas da vasopressina
FI98872B (fi) Parannettu portaittain säädettävä suodatin
DK0814890T3 (da) Gasfilterenhed
ATE381570T1 (de) Trizyclische benzazepin-vasopressin-antagoniste
FI98990B (fi) Suodatin
NO983023D0 (no) Plagg for personlig beskyttelse
FI956004A0 (fi) Filter
ATE207292T1 (de) Fungizide mischung
DE19680345D2 (de) Filteranordnung
ATE204127T1 (de) Fungizide mischung
DE59602832D1 (de) Filteranordnung
FI965116A (fi) Uusia opioidipeptidiantagonisteja
SI0873309T1 (en) 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
KR970000625U (ko) 용접용 나사공 보호구
IT239843Y1 (it) Filtro
KR970004362U (ko) 여과기용 필터
DE69632064D1 (de) Neue tyrosinkinase-rezeptoren und liganden
BR7500941U (pt) Poncho
SE9502282L (sv) Multiadressanropssätt
FI2256U1 (fi) Suodatin
KR960006660U (ko) 스피커용 팩킹

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121024